Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization

Authors: Ji-Young Jang, Jong-Kuen Lee, Yoon-Kyung Jeon, Chul-Woo Kim

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Tumor-associated macrophages (TAM) play an important role in tumor microenvironment. Particularly, M2 macrophages contribute to tumor progression, depending on the expression of NF-κB. Tumor-derived exosomes can modulate tumor microenvironment by transferring miRNAs to immune cells. Epigallocatechin gallate (EGCG) has well known anti-tumor effects; however, no data are available on the influence of EGCG on communication with cancer cells and TAM.

Methods

Murine breast cancer cell lines, 4T1, was used for in vivo and ex vivo studies. Exosome was extracted from EGCG-treated 4T1 cells, and the change of miRNAs was screened using microarray. Tumor cells or TAM isolated from murine tumor graft were incubated with exosomes derived from EGCG-treated and/or miR-16 inhibitor-transfected 4T1 cells. Chemokines for monocytes (CSF-1 and CCL-2), cytokines both with high (IL-6 and TGF-β) and low (TNF-α) expression in M2 macrophages, and molecules in NF-κB pathway (IKKα and Iκ-B) were evaluated by RT-qPCR or western blot.

Results

EGCG suppressed tumor growth in murine breast cancer model, which was associated with decreased TAM and M2 macrophage infiltration. Expression of chemokine for monocytes (CSF-1 and CCL-2) were low in tumor cells from EGCG-treated mice, and cytokines of TAM was skewed from M2- into M1-like phenotype by EGCG as evidenced by decreased IL-6 and TGF-β and increased TNF-α. Ex vivo incubation of isolated tumor cells with EGCG inhibited the CSF-1 and CCL-2 expression. Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1 cells led to IKKα suppression and concomitant I-κB accumulation; increase of IL-6 and TGF-β; and, decrease of TNF-α. EGCG up-regulated miR-16 in 4T1 cells and in the exosomes. Treatment of tumor cells or TAM with exosomes derived from EGCG-treated and miR-16-knock-downed 4T1 cells restored the above effects on chemokines, cytokines, and NF-κB pathway elicited by EGCG-treated exosomes.

Conclusions

Our data demonstrate that EGCG up-regulates miR-16 in tumor cells, which can be transferred to TAM via exosomes and inhibits TAM infiltration and M2 polarization. We suggest a novel mechanism by which EGCG exerts anti-tumor activity via regulation of TAM in tumor microenvironment.
Appendix
Available only for authorised users
Literature
1.
Gezgen G, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K: Metabolic syndrome and breast cancer: an overview. J Buon. 2012, 17: 223-229.PubMed
2.
3.
Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC: Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004, 7: 187-200.CrossRefPubMed
4.
Yang CS, Sang S, Lambert JD, Hou Z, Ju J, Lu G: Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res. 2006, 50: 170-175.CrossRefPubMed
5.
Mukhtar H, Ahmad N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 2000, 71: 1698S-1702S.PubMed
6.
Lambert JD, Hong J, Yang GY, Liao J, Yang CS: Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr. 2005, 81: 284S-291S.PubMed
7.
Stuart EC, Scandlyn MJ, Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci. 2006, 2006 (79): 2329-2336.CrossRef
8.
Zhang G, Miura Y, Yagasaki K: Effects of green, oolong and black teas and related components on the proliferation and invasion of hepatoma cells in culture. Cytotechnology. 1999, 31: 37-44.CrossRefPubMedPubMedCentral
9.
Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS: Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006, 66: 11494-11501.CrossRefPubMed
10.
Lu YP, Lou YR, Xie JG, et al: Topical applications of caffeine or (−)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci U S A. 2002, 99: 12455-12460.CrossRefPubMedPubMedCentral
11.
Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK: Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2007, 245: 232-241.CrossRefPubMed
12.
Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004, 64: 8715-8722.CrossRefPubMed
13.
Wang ZY, Huang MT, Ho CT, et al: Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res. 1999, 52: 6657-6665.
14.
Heijnen HF, Schiel AE, Fijnheer R, et al: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alphagranules. Blood. 1999, 94: 3791-3799.PubMed
15.
Rozmyslowicz T, Majka M, Kijowski J, et al: Platelet- and megakaryocytederived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS. 2003, 17: 33-42.CrossRefPubMed
16.
Majka M, Janowska-Wieczorek A, Ratajczak J, et al: Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001, 97: 3075-3085.CrossRefPubMed
17.
Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003, 39: 184-191.CrossRefPubMed
18.
Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L: Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008, 15: 80-88.CrossRefPubMed
19.
Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB: Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005, 4: 1595-1604.CrossRefPubMed
20.
Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V: Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007, 9: 349-357.CrossRefPubMedPubMedCentral
21.
Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C: Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011, 1: 98-110.PubMed
22.
23.
Bingle L, Brown NJ, Lewis CE: The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol. 2002, 196: 254-265.CrossRefPubMed
24.
Leek RD, Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002, 7: 177-189.CrossRefPubMed
25.
Antonio S, Tiziana S, Alberto M, Paola A: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer. 2006, 42: 717-727.CrossRef
26.
Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A: p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66: 11432-11440.CrossRefPubMed
27.
Mantovani A, Marchesi F, Porta C, Sica A, Allavena P: Inflammation and cancer: breast cancer as a prototype. Breast. 2007, 16: S27-S33.CrossRefPubMed
28.
Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826.CrossRefPubMed
29.
Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG: MicroRNAs modulate the noncanonical NF-κB pathway by regulating IKKα expression during macrophage differentiation. Nat Immunol. 2010, 11: 799-805.CrossRefPubMedPubMedCentral
30.
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR: Re-educating tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008, 205: 1261-1268.CrossRefPubMedPubMedCentral
31.
Shih JY, Jeremy AY, Chen JW, Yang PC: Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol. 2006, 2: 101-106.
32.
Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C: Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracellular Vesicles. 2012, 1: 18397-CrossRef
33.
Chew V, Toh HC, Abastado JP: Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012, 2012: 1-10.CrossRef
34.
35.
Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L: Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010, 78: 838-848.CrossRefPubMed
36.
Rustom A, Saffrich R, Markovic I, et al: Nanotubular highways for intercellular organelle transport. Science. 2004, 303: 1007-1010.CrossRefPubMed
37.
38.
Ratajczak J, Wysoczynski M, Hayek F, et al: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006, 20: 1487-1495.CrossRefPubMed
39.
40.
Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008, 10: 1470-1476.CrossRefPubMedPubMedCentral
41.
42.
Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM: Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010, 5: e13515-CrossRefPubMedPubMedCentral
43.
Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008, 36: 5391-5404.CrossRefPubMedPubMedCentral
44.
Ofir M, Hacohen D, Ginsberg D: miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res. 2011, 9: 440-447.CrossRefPubMed
45.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D’Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008, 14: 1271-1277.CrossRefPubMed
46.
Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T: Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010, 18: 181-187.CrossRefPubMed
47.
Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X: Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 2010, 70: 7176-7186.CrossRefPubMedPubMedCentral
48.
Thorsten H, Subhra KB, Toby L, Antonio S, Claire EL: Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood. 2009, 113: 3139-3146.CrossRef
Metadata
Title
Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization
Authors
Ji-Young Jang
Jong-Kuen Lee
Yoon-Kyung Jeon
Chul-Woo Kim
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-421

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Primary Tumor Vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact

Research article

Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma

Research article

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Research article

Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients

Research article

Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study

Study protocol

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits